NCT03680144
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one identifiable intracranial lesion ≥ 1 cm in diameter enrolled within 4 weeks of diagnosis
Exclusions: Patients with leptomeningeal disease
https://clinicaltrials.gov/show/NCT03680144